SCHEMBL5535987

SCHEMBL5535987

CC(C)CC1COC(=O)O1

nearest known ligand 0.45

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24678329 0.81
SCHEMBL20955973 0.80 HTT (0.35) PIK3CD
SCHEMBL2034322 0.79
SCHEMBL16161757 0.78
SCHEMBL25906805 0.77 HTT (0.31) PIK3CD
SCHEMBL27909762 0.76 CA1 (0.36) PIK3CD
SCHEMBL20962225 0.76 CA2 (0.31) PIK3CD
SCHEMBL10354500 0.76 MAPT (0.45) PIK3CD
SCHEMBL74916 0.76
SCHEMBL2364933 0.76 MAOA (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4600742-A2 INCREASING EFFICIENCY OF PHOTOCHEMICAL REACTIONS ON SUBSTRATES Centrillion Technologies, Inc. (US) 2025-08-13 EP disclosed
US-20250205671-A1 Increasing Efficiency Of Photochemical Reactions On Substrates CENTRILLION TECHNOLOGIES, INC. 2025-06-26 US disclosed
US-11780852-B2 Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-10-10 US disclosed
US-20230092024-A1 Increasing Efficiency Of Photochemical Reactions On Substrates CENTRILLION TECHNOLOGIES, INC. 2023-03-23 US disclosed
US-11197818-B2 Aqueous emulsions of carbamato-functionalized organopolysiloxanes WACKER CHEMIE AG (DE) 2021-12-14 US disclosed
CN-109152723-B Aqueous emulsions of carbamate-functional organopolysiloxanes 瓦克化学股份公司 2021-11-09 CN disclosed
CN-108779415-B Composition containing carbamate-functional organopolysiloxane and cationic surfactant 瓦克化学股份公司 2021-11-05 CN disclosed
US-20210179637-A1 NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-06-17 US disclosed
EP-3802847-A1 INCREASING EFFICIENCY OF PHOTOCHEMICAL REACTIONS ON SUBSTRATES Centrillion Technologies, Inc. (US) 2021-04-14 EP disclosed
US-10675230-B2 Compositions comprising carbamate functionalized organopolysiloxanes and cationic surfactants WACKER CHEMIE AG (DE) 2020-06-09 US disclosed
US-20190133919-A1 AQUEOUS EMULSIONS OF CARBAMATO-FUNCTIONALIZED ORGANOPOLYSILOXANES WACKER CHEMIE AG (DE) 2019-05-09 US disclosed
US-20190133906-A1 COMPOSITIONS COMPRISING CARBAMATE FUNCTIONALIZED ORGANOPOLYSILOXANES AND CATIONIC SURFACTANTS WACKER CHEMIE AG (DE) 2019-05-09 US disclosed
US-9246187-B2 Non-aqueous electrolyte for lithium-ion battery UCHICAGO ARGONNE, LLC (US) 2016-01-26 US disclosed
US-20140272607-A1 NON-AQUEOUS ELECTROLYTE FOR LITHIUM-ION BATTERY UCHICAGO ARGONNE LLC (US) 2014-09-18 US disclosed
US-20070178379-A1 Non-aqueous electrolyte secondary battery and non-aqueous electrolyte SANYO ELECTRIC CO., LTD. (JP) 2007-08-02 US disclosed
EP-1806806-A1 NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY AND NON-AQUEOUS ELECTROLYTE Sanyo Electric Co., Ltd. (JP) 2007-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10675230-B2 Compositions comprising carbamate functionalized organopolysiloxanes and cationic surfactants C9, CUTA, NISCH PIK3CD 2185/4885
US-11780852-B2 Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile ALPI, TPMT, SLC10A2 PIK3CD 1840/4885
US-11197818-B2 Aqueous emulsions of carbamato-functionalized organopolysiloxanes HMBS, CBLB, LIPA PIK3CD 1838/4885
US-20190133906-A1 COMPOSITIONS COMPRISING CARBAMATE FUNCTIONALIZED ORGANOPOLYSILOXANES AND CATIONIC SURFACTANTS C9, CUTA, NISCH PIK3CD 2185/4885
US-20190133919-A1 AQUEOUS EMULSIONS OF CARBAMATO-FUNCTIONALIZED ORGANOPOLYSILOXANES HMBS, CBLB, LIPA PIK3CD 1838/4885
US-20230092024-A1 Increasing Efficiency Of Photochemical Reactions On Substrates TYR, PCNA, DNMT1 PIK3CD 2792/4885
US-20210179637-A1 NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS JAK1, JAK2, JAK3 PIK3CD 113/4885
US-20250205671-A1 Increasing Efficiency Of Photochemical Reactions On Substrates TYR, PCNA, DNMT1 PIK3CD 2792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.